

For Immediate Release

M a r c h 1 1 , 2 0 0 2

Kyorin Pharmaceutical Co., Ltd.

2-5 Surugadai, Kanda, Chiyoda-ku, Tokyo

(Stock code: 4560, TSE 1st Section)

Kyorin Europe GmbH opens its doors for business

On March 8, 11:30am local time, an opening ceremony was performed and business commenced for Kyorin Europe GmbH, located in Frankfurt, Germany, as a base for business development in Europe. Kyorin Europe GmbH is a wholly-owned subsidiary of Kyorin Pharmaceutical Co., Ltd (President: Ikuo Ogihara)

In Europe, Kyorin Pharmaceutical has licensed out its proprietary drugs, including Gatifloxacin, Norfloxacin and HES to its local partners. Currently, Kyorin's licensing partners are conducting clinical trials of our diabetes agent KRP-297 and intravenous Gatifloxacin.

Kyorin Europe GmbH was established in order to accelerate our entrance into the European market and will be involved in a number of activities to support this effort including the management of current business projects with European partners, research, analysis and negotiations with new license partner candidates, obtaining data on European pharmaceutical companies and supporting clinical trials conducted locally. With the start of Kyorin Europe GmbH and Kyorin USA in April last year, Kyorin Pharmaceutical has established business development bases in Europe and the US in addition to Japan. Going forward, the company seeks to strengthen its overseas business.

Finally, Kyorin Europe GmbH is currently staffed by four employees including one local employee.

Summary of Kyorin Europe GmbH

Company Name: Kyorin Europe GmbH

Address: Kaiserstrasse 8, 60311 Frankfurt am Main

Capital: 50,000 Euro

Telephone: +49-69-13885-00

Facsimile: +49-69-133885-015

Date established: February 13, 2002

Start of operations: March 8, 2002

Managing Director : Tatsushi Imaizumi

End of announcement